Dupilumab

Drug Profile

Dupilumab

Alternative Names: Dupixent; REGN 668; SAR 231893

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor type I antagonists; Interleukin 4 receptor type II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Phase III Asthma; Nasal polyps
  • Phase II Eosinophilic oesophagitis
  • Phase I Allergic asthma

Most Recent Events

  • 03 Aug 2017 Regeneron Pharmaceuticals announces intention to submit a BLA to USFDA for Asthma (In adolescents, In adults) (uncontrolled asthma) in second half of 2017
  • 03 Aug 2017 Regeneron Pharmaceuticals plans a phase III trial for Atopic dermatitis (In children) in 2017
  • 21 Jul 2017 Committee for Medicinal Products for Human Use (CHMP) of EMA recommends approval of dupilumab for Atopic dermatitis (Monotherapy, Adjunctive therapy, In adults) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top